FDA may encourage direct talks with sponsors to answer questions about combination product development, but at some point the agency has to issue more paper outlining its regulatory practices, an industry official said.
Written guidance can help sponsors make early development decisions easier, Bradley Merrill Thompson, of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?